Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.79 |
| ▸ | TCF4 | P15884 | 2/20 | 0.79 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.79 |
| ▸ | CLPP | Q16740 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.38 |
| ▸ | TCF7 | P36402 | 2/20 | 0.37 |
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15477009 | 0.99 | CTNNB1 (0.80) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL23668060 | 0.99 | CTNNB1 (0.80) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL1592280 | 0.92 | CTNNB1 (0.83) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL15648154 | 0.92 | CTNNB1 (0.83) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL15647478 | 0.92 | CTNNB1 (0.83) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL1592209 | 0.90 | CTNNB1 (0.64) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL15476709 | 0.90 | CTNNB1 (0.87) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL16966310 | 0.90 | CTNNB1 (0.65) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL1592416 | 0.89 | CTNNB1 (0.99) | CTNNB1TCF4CREBBPCLPPCYP3A4 | |
| SCHEMBL15309402 | 0.89 | CTNNB1 (0.76) | CTNNB1TCF4CREBBPCLPPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193734-B2 | Alpha helix mimetics and methods relating thereto | PRISM PHARMA CO., LTD. (JP) | 2015-11-24 | — | — | US | disclosed |
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM PHARMA CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8455488-B2 | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORPORATION (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267482-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | CTNNB1 416/4885TCF4 572/4885CREBBP 569/4885 |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | CTNNB1 416/4885TCF4 572/4885CREBBP 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.